Non-Small Cell Lung Cancer Therapeutics Market Worth USD 43,713.1 Million at 13.4% CAGR Forecast by 2026

The Global Non-Small Cell Lung Cancer Market is likely to gain immense traction in the coming years. Driven by the increasing incidence of non-small cell lung cancer, Fortune Business Insights sees promising growth on cards. According to a report published by Fortune Business Insights, titled “Non-Small Cell Lung Cancer Therapeutics Market: Global Market Analysis, Insights and Forecast, 2019-2026,” the market was valued at US$ 16,011.7 Mn in 2018.

On account of an upscale in demand for improved non-small cell lung caner treatment, Fortune Business Insights makes a stellar CAGR prediction, forecasting it to be 13.4%. At this pace, the market will be valued at US$ 43,713.1 Mn by the end of 2026.

According to the WHO, non-small cell lung cancer accounts for 80-85% of the total cases of lung cancer, worldwide. These numbers are indicative of the high prevalence of non-small cell lung cancer cases around the world and it is the leading factor that will drive the market in the forecast period.

In order to curb the prevalence of non-small cell lung cancer, governments around the world are focusing more on minimizing fatality rate due to this disease. Various awareness programs are therefore conducted and initiatives have been taken by government as well as private organizations to minimize the effect of non-small cell lung cancer, globally.

Targeted Therapy to Emerge as the Leading Segment

The high efficiency of targeted therapies has increased their adoption among end users. Targeted therapies have more advantages than drawbacks and this is a major reason why they have an upper hand over their therapy alternatives. Further improvements in this therapy are brought about to facilitate lung cancer treatment.

The aforementioned factors will favour the targeted therapy segment and this is likely to emerge as the leading segment throughout the forecast period. As of 2018, targeted therapies accounted for more than 50% of the total share in the global non-small cell lung cancer therapeutics market.

Advancements in Non-Small Cell Lung Cancer Therapeutics Favor Growth of Market in Asia Pacific 

Adoption of unhealthy habits leading to non-small cell lung cancer is a major factor that drives the regional market. Smoking accounts for a most of the lung cancer cases in this region. Besides, frequent exposure to toxins such as asbestos and other elements of air pollution in Asia Pacific is also contributing to the growth of the non-small cell lung cancer market in this region.

Increasing adoption of chemotherapy and targeted therapy in the developing market of India and China are boosting the market in Asia-Pacific.  The aforementioned factors are likely to favor the growth of the non-small cell lung cancer therapeutics market in Asia Pacific in the forecast period. 

Genentech Inc. To Emerge as The Leading Company in The Forecast Period

With numerous product offerings, Genentech Inc has emerged as the leading company in the global non-small cell lung cancer therapeutics market. The company is focusing on the most widely adopted therapies which are immunotherapy and targeted therapy.

Some of the other companies that are operating in the global non-small cell lung cancer therapeutics market are Boehringer Ingelheim Pharmaceuticals, Inc., Eli Lilly, and Company, Celgene Corporation, AstraZeneca, Pfizer Inc., Sanofi, Novartis AG, Millennium Pharmaceuticals, Inc. (Takeda), Bristol Myers Squibb, and Merck Sharp & Dohme Corp., and Astellas.

Browse Complete  Report Details: https://www.fortunebusinessinsights.com/industry-reports/non-small-cell-lung-cancer-therapeutics-market-100484

The global non-small cell lung cancer therapeutics market is segmented based on: